iTeos Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ITOS research report →
About the company
iTeos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the discovery and advancement of immuno-oncology therapies for patients. The company's pipeline includes two principal investigational drugs: inupadenant, a small molecule designed as an antagonist of adenosine A2AR, which is currently undergoing Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT (T-cell immunoreceptor with Ig and ITIM domains), presently in Phase 1/2 clinical assessment.
- CEO
- Michel Detheux
- IPO
- 2020
- Employees
- 173
- HQ
- Watertown, MA, US
Price Chart
- Market Cap
- $448.68M
- P/E
- -3.89
- P/S
- 0.00
- P/B
- 0.90
- EV/EBITDA
- -2.46
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -21.44%
- ROIC
- -22.34%
- Revenue
- $35.00M · 177.89%
- Net Income
- $-134,414,000 · -19.33%
- EPS
- $-3.32 · -5.40%
- Op Income
- $-159,528,000
- FCF YoY
- 6.47%
- 52W High
- $17.63
- 52W Low
- $4.80
- 50D MA
- $10.13
- 200D MA
- $8.29
- Beta
- 1.49
- Avg Volume
- 1.34M
Get TickerSpark's AI analysis on ITOS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 29, 25 | Call Matthew | sell | 135,937 |
| Aug 29, 25 | Call Matthew | sell | 146,835 |
| Aug 29, 25 | Call Matthew | sell | 66,170 |
| Aug 29, 25 | Call Matthew | other | 161,898 |
| Aug 29, 25 | Detheux Michel | sell | 52,700 |
| Aug 29, 25 | Detheux Michel | sell | 444,815 |
| Aug 29, 25 | Detheux Michel | sell | 185,000 |
| Aug 29, 25 | Detheux Michel | other | 94,027 |
| Aug 29, 25 | Lee David K | sell | 23,625 |
| Aug 29, 25 | Feltquate David | other | 47,000 |
Our ITOS coverage
Recent articles, reports, and earnings notes.
No research on ITOS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ITOS report →Similar companies
Peers in the same neighborhood.